- Posted July 23, 2015
- Tweet This | Share on Facebook
Court ruling clears way for low-cost biotech drug
WASHINGTON (AP) - A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication.
Novartis received federal approval in March to sell its cheaper copy of Amgen's Neupogen, which is used to boost blood cells in cancer patients. It was the first time the Food and Drug Administration had approved a lower-cost copy of a biotech drug.
But the launch of Novartis' Zarxio has been delayed by litigation brought by Amgen Inc.
On Tuesday, the U.S. Court of Appeals for the Federal Circuit rejected Amgen's claims of unfair competition but also said Novartis would have to wait until Sept. 2 before selling its drug.
The delayed launch stems from a provision of the law governing approval of biosimilars, the industry term for the quasi-generic biotech drugs. The court ruling handed down Tuesday states that companies marketing new biosimilars must give 180 days advance notice to the original drugmaker after receiving FDA approval. Novartis had argued that the 180 days' notice could be given prior to FDA approval.
The court ruling means biotech makers like Amgen Inc. can expect six additional months of exclusive marketing for their drugs even after a biosimilar is approved.
In Europe, Novartis has sold its version of Neupogen, called Zarzio there, since 2009. The drugmaker also markets two other biosimilar drugs in about 60 countries.
Other blockbuster biotech drugs expected to face biosimilar competition in the U.S. include anti-inflammatory drugs Remicade and Humira and cancer drugs Herceptin and Avastin.
Published: Thu, Jul 23, 2015
headlines Oakland County
- Annual Dinner & Meeting
- Federal court denies motion to reopen election lawsuit
- Longtime law professor known for her pioneering research honored with ABA Michael Franck Professional Responsibility Award
- Whitmer signs bipartisan bill to drive investment and job creation in local communities
- Leadership Webinar Series looks into ‘Courageous Conversations’
headlines National
- More lawyers—and clients—want to learn about sustainable development practices
- Top artificial intelligence insurance tips for lawyers
- Lawyer charged with illegally transmitting Michigan data after 2020 election
- Viral video shows former Rikers Island inmate as she learns she passed bar exam on first try
- How Sullivan & Cromwell is scrutinizing potential new hires after campus protests
- No separate hearing required when police seize cars loaned to drivers accused of drug crimes, SCOTUS rules